Breaks Categories: News

FridayJun 23, 2023 2:25 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug Administration’s approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is expected to continue increasing at a compound annual growth rate of 4% over the next decade. Meanwhile,…

Continue Reading

FridayJun 23, 2023 12:11 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a video published by InvestmentPitch Media. FSD Pharma recently entered into a non-binding letter of intent with 1319741 B.C. Ltd., an unlisted reporting issuer, which will be renamed Celly Nutrition Inc. FSD Pharma and Celly Nutrition (“Celly Nu”) intend to enter into a definitive licensing and loan agreement whereby FSD will provide Celly Nu an exclusive license to commercialize products developed using FSD’s IP for alcohol misuse…

Continue Reading

WednesdayJun 21, 2023 2:20 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development…

Continue Reading

TuesdayJun 20, 2023 12:07 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced its entry into a non-binding letter of intent. The agreement, dated June 19, 2023, is with 1319741 B.C. Ltd., which will be renamed “Celly Nutrition Inc.” (“Celly Nu”), an unlisted reporting issuer, and sets forth the basic terms and conditions upon which Celly Nu will be granted exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology designed to accelerate alcohol detoxification. FSD Pharma will…

Continue Reading

ThursdayMay 25, 2023 2:41 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the appointment of Dr. Eric Hoskins to its board of directors. A medical doctor, Dr. Hoskins is specialized in public health and presently a partner at Maverix Private Equity in Toronto. From 2014 to 2018, he was Ontario’s Minister of Health and Long-Term Care. His esteemed career spans nearly four decades, where Dr. Hoskins has built a reputation of expertise in public health,…

Continue Reading

TuesdayMay 16, 2023 1:22 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company has been awarded approximately C$2.81 million in an arbitration settlement. An InvestmentPitch Media video provides additional information about this news and the company. The video is available for viewing on InvestmentPitch and YouTube. To view the full press release, visit https://ibn.fm/3Mr4e About FSD Pharma Inc. FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, a wholly owned…

Continue Reading

MondayMay 15, 2023 1:09 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that a complaint against the company and its subsidiary, FSD Biosciences Inc., was filed on May 1, 2023. The complaint was filed in the United States District Court for the Southern District of Florida by GBB Drink Lab Inc. FSD Pharma received a copy of the complaint on May 9, 2023. According to the announcement, the complaint states that “FSD breached a mutual nondisclosure agreement and…

Continue Reading

ThursdayMay 11, 2023 2:27 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced that in a cost award decision dated May 6, 2023, the Honorable J. Douglas Cunningham, K.C. (“Justice Cunningham”) ruled in favor of FSD Pharma, awarding the company approximately $2.81 million all in Canadian dollars costs of arbitration in the arbitration between FSD Pharma and its former CEO Dr. Raza Bokhari. In July 2021, the board of directors for FSD Pharma unanimously voted to…

Continue Reading

WednesdayMay 10, 2023 1:37 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has completed dosing the first cohort of patients in its phase I clinical trial of Lucid-21-302 (Lucid-MS). According to the announcement, the study, which is being conducted by Lucid Psycheceuticals, the company’s wholly owned subsidiary, is the first-in-human study designed to evaluate Lucid-MS as a novel drug candidate for the treatment of multiple sclerosis (“MS”). A small molecule inhibitor of hypercitrullination, Lucid-MS is a patented first-in-class, new chemical…

Continue Reading

TuesdayMay 09, 2023 2:52 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has received a patent from the U.S. Patent and Trademark Office (“USPTO”). Titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,” the patent claims cover the use of biomarkers in determining the efficacy of SILO’s portfolio drug SPC-15. SPC-15 is a targeted prophylactic treatment that uses ketamine compositions as a key component for treating stress-induced affective disorder or stress-induced psychopathology. According to the announcement, the company owns an option to license specific assets of which the patent forms a part. SPC-15…

Continue Reading